Open-Label Pre and Post Treatment Arthroscopic Synovial Biopsy Study for the Assessment of Certolizumab Pegol Immunomodulatory Synovial Effects on Select Biomarkers and Gene Expression.
Phase of Trial: Phase III
Latest Information Update: 07 Apr 2014
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics; Pharmacokinetics
- 07 Jun 2017 Biomarkers information updated
- 03 Oct 2011 Actual initiation date (Sep 2011) added as reported by ClinicalTrials.gov.
- 03 Oct 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.